US lawmakers seek to end China's special trade status, import duty exemption

Published 01/23/2025, 01:14 PM
Updated 01/23/2025, 04:41 PM
© Reuters. FILE PHOTO: U.S. President Donald Trump attends a bilateral meeting with China's President Xi Jinping during the G20 leaders summit in Osaka, Japan, June 29, 2019. REUTERS/Kevin Lamarque/File Photo

By Michael Martina

WASHINGTON (Reuters) -U.S. lawmakers introduced a bipartisan bill on Thursday that would revoke China's preferential trade status with the United States, phase in steep tariffs and end the "de minimis" exemption for low-value Chinese imports.

The bill, introduced by John Moolenaar, the Republican chair of the House of Representatives' select committee on China, comes after President Donald Trump issued a memo on Monday asking his cabinet to assess legislation on the Permanent Normal Trade Relations designation for Beijing.

Congress approved PNTR for China in 2000, paving the way for its entry into the World Trade Organization. But the U.S. has routinely found the large role of the state in China's economy, including hefty government subsidies for strategic industries, to violate the global trade body's rules.

Trump, who has railed against China's vast trade surplus with the U.S., has vowed more duties on Chinese goods.

Moolenaar's Restoring Trade Fairness Act was co-sponsored by Democratic Representative Tom Suozzi and introduced with a companion bill in the Senate. Moolenaar said granting China PNTR had ushered in waves of Chinese imports, depleted U.S. manufacturing and made the U.S. susceptible to economic coercion from its "foremost adversary."

"This gamble failed," Moolenaar said in a statement. "This legislation will safeguard U.S. national security, enhance supply chain resilience, and bring manufacturing jobs back to America and our allies."

China's embassy in Washington said any such move would harm both Chinese and U.S. interests.

"Some U.S. politicians are trying to reverse history and drag Sino-U.S. economic and trade relations back to the Cold War era," embassy spokesperson Liu Pengyu said.

The path for the bill to become law was not immediately clear, but Republicans hold majorities in both the House and Senate. Lawmakers from both parties say they want to increase U.S. companies' ability to compete with China.

Waves of U.S. tariffs by Trump in his first term and by the Biden administration had effectively ended PNTR treatment for China.

Nonetheless, the proposed legislation would end annual recertification of the designation, and codify minimum 35% tariffs for non-strategic goods and minimum 100% tariffs for strategic goods. The duties would be phased in over five years - 10% in the first year, 25% in the second year, 50% in year four and 100% by year five.

The bill would also end de minimis treatment for certain "covered nations," including China.

© Reuters. FILE PHOTO: U.S. President Donald Trump attends a bilateral meeting with China's President Xi Jinping during the G20 leaders summit in Osaka, Japan, June 29, 2019. REUTERS/Kevin Lamarque/File Photo

Trump has called for changes to the $800 de minimis duty-free exemption for low-value shipments often blamed for illicit imports of fentanyl precursor chemicals from China.

Critics of de minimis say it contributes to the United States' trade deficit with China - $279 billion in 2023, according to the U.S. Census Bureau.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.